Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 9/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998196 | 0.88 | PTPN1 (0.53) | PTPN1TLR4STAT3POLBCTDSP1 | |
| SCHEMBL10042261 | 0.85 | PTPN1 (0.33) | PTPN1 | |
| SCHEMBL14010919 | 0.81 | PTPN1 (0.46) | PTPN1TLR4STAT3POLBCTDSP1 | |
| SCHEMBL13998040 | 0.78 | PTPN1 (0.40) | PTPN1TLR4STAT3POLBCTDSP1 | |
| Shanzhiside Methyl Ester SCHEMBL28007134 | 0.74 | POLB (0.62) | STAT3POLBCTDSP1MEN1MAPT | |
| Shanzhiside Methyl Ester SCHEMBL12207355 | 0.74 | POLB (0.62) | STAT3POLBCTDSP1MEN1MAPT | |
| Shanzhiside Methyl Ester SCHEMBL29965826 | 0.74 | POLB (0.62) | STAT3POLBCTDSP1MEN1MAPT | |
| SCHEMBL14010694 | 0.69 | POLB (0.39) | PTPN1TLR4STAT3POLBCTDSP1 | |
| SCHEMBL13998037 | 0.69 | PTPN1 (0.43) | PTPN1TLR4STAT3POLBCTDSP1 | |
| SCHEMBL10042268 | 0.66 | TLR4 (0.80) | TLR4STAT3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | CALECO PHARMA CORP. | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | HCCS, HAVCR2, PYGL | PTPN1 3880/4885TLR4 2654/4885STAT3 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.